bl-b01d1
biokin pharma
['solid tumor', 'bl-b01d1', 'nsclc', 'sclc']
#asco23 bl-b01d1, a first-in-class egfrxher3 bispecific adc, in patients with locally advanced or metastatic solid tumor 195 pts orr
all pts 45.3%
egfrmt nsclc 63%
egfrw nsclc 45% presented by dr. li zhang 
Medical Oncologist.                                            
        
On the trail of #SCIENCE to turn cancer into a manageable chronic disease. #bcsm #crcsm